Gauss Announces Triton Platform Update to Power Maternal Hemorrhage Response
Triton QBL integrates hemorrhage protocols and provider alerts and supports hospital compliance with new Joint Commission perinatal safety standard
Menlo Park, Calif. – September 25, 2019 – Gauss, the leader in AI-enabled surgical applications, announced an over-the-air software update, Triton QBL, that pairs the company’s AI-powered blood loss monitor with integrated protocols and provider alerts that help to synchronize postpartum hemorrhage care. The update will be available to the company’s network of hospital customers this fall.
The United States has the highest maternal mortality rate in the developed world1. According to the Centers for Disease Control and Prevention (CDC), 60 percent of pregnancy-related deaths are preventable2. Postpartum hemorrhage is the leading preventable cause of maternal morbidity and mortality3, and obstetrics organizations such as the American College of Obstetrics and Gynecology (ACOG) and the California Maternal Quality Care Collaborative (CMQCC) recommend use of standardized hemorrhage management protocols4,5.
On August 21, 2019, The Joint Commission, the body that accredits approximately 77 percent of hospitals in the United States, announced a perinatal safety guideline that requires accredited hospitals to “develop written, evidence-based procedures for stage-based management of pregnant and postpartum patients who experience maternal hemorrhage” incorporating “the use of an evidence-based tool that includes an algorithm for identification and treatment of hemorrhage.”6 This new standard will go into effect July 1, 2020.
“Management of maternal hemorrhage with stage-based protocols based on cumulative, quantitative blood loss is imperative for safe obstetric care,” said David Lagrew, M.D., executive medical director of Women’s Services at Providence St. Joseph’s Health and co-chair of the CMQCC Maternal Quality Care Collaborative’s Hemorrhage Task Force. “We have adopted the Triton platform across multiple facilities at Providence, and the integration of hemorrhage protocols and provider alerts will help us to deliver the best quality of maternal care, consistent with the Joint Commission’s new perinatal safety standard.”
Triton is the only FDA-cleared and CE Marked system for blood loss monitoring in surgery and obstetrics. It leverages computer vision and the CoreML capability of the iPad and iPhone to monitor blood loss from images captured by the TrueDepth sensor. Triton adoption has grown by more than 100 percent year-over-year, and Gauss’s U.S. customers perform approximately 250,000 deliveries per year7. Researchers at Mount Sinai Hospital in New York recently published an independent 7,600 patient study in the International Journal of Obstetric Anesthesia on the use of Triton to power a stage-based hemorrhage protocol. The use of Triton was associated with a 340 percent increase in hemorrhage recognition, a 34 percent reduction in delayed interventions to control bleeding in vaginal deliveries, reduced transfusion dose in Caesarean sections, and cost savings leading to a 152 percent return on investment8.
Triton QBL is compatible with both iPhone and iPad platforms and enables hospitals to embed their own hemorrhage protocols and set customized alerts based on quantified blood loss (QBL) thresholds, delivering real-time guidance to clinicians and facilitating communication and rapid response during an emerging hemorrhage. U.S. hospitals are rapidly adopting smartphones to improve communication and collaboration among clinical teams9, and Triton’s new iPhone compatibility delivers a mobile platform that enables health systems to leverage their IT investment in enterprise-issued phones.
“We are incredibly excited about this significant evolution of the Triton system to power hemorrhage protocols and support better maternal care,” said Siddarth Satish, founder and chief executive officer of Gauss. “With hundreds of thousands of enterprise-issued iPhones in use by clinical staff in hospitals today, these latest developments enable us to extend the benefits of our AI-enabled patient safety platform to many more patients and healthcare providers.”
About Gauss Gauss is transforming surgery with an AI-enabled mobile platform for the operating room. Based in Silicon Valley, the company leverages computer vision, machine learning, and artificial intelligence to power surgical safety protocols by delivering real-time insights, simplifying clinical workflow, and closing communication gaps. The company’s flagship Triton platform is FDA cleared and CE Marked and powers maternal hemorrhage protocols in hospitals performing over 250,000 annual deliveries. Triton received the 2018 Apple Design Award, which recognizes the best in design, innovation and technology on Apple platforms. For more information, visit http://www.gauss.com.
(1) Kassebaum NJ, Barber RM, Bhutta ZA, et al; GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1775-1812.
(2) Petersen EE, Davis NL, Goodman D, Cox S, Mayes N, Johnston E, et al. Vital signs: pregnancy-related deaths, United States, 2011-2015, and strategies for prevention, 13 states, 2013-2017. MMWR Morb Mortal Wkly Rep 2019;68:423–9.
(7) American Hospital Association Data and Gauss Internal Estimates
(8) Katz D, Wang R, O’Neil L, Gerber C, Lankford A, Rogers T, Gal J, Sandler R, Beilin Y., et al. The association between the introduction of quantitative assessment of postpartum blood loss and institutional changes in clinical practice: an observational study. Int J Obstet Anesth. 2019 May 13. pii: S0959-289X(19)30070-6. doi: 10.1016/j.ijoa.2019.05.006. [Epub ahead of print]